BR0312152A - método de produção de lipossomos contendo um composto biologicamente ativo, e composição de lipossomos - Google Patents

método de produção de lipossomos contendo um composto biologicamente ativo, e composição de lipossomos

Info

Publication number
BR0312152A
BR0312152A BRPI0312152-6A BR0312152A BR0312152A BR 0312152 A BR0312152 A BR 0312152A BR 0312152 A BR0312152 A BR 0312152A BR 0312152 A BR0312152 A BR 0312152A
Authority
BR
Brazil
Prior art keywords
liposome
biologically active
active compound
production method
method containing
Prior art date
Application number
BRPI0312152-6A
Other languages
English (en)
Inventor
Scott A Mclean
William R Campbell
Original Assignee
Piedmont Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piedmont Pharmaceuticals Llc filed Critical Piedmont Pharmaceuticals Llc
Publication of BR0312152A publication Critical patent/BR0312152A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MéTODO DE PRODUçãO DE LIPOSSOMOS CONTENDO UM COMPOSTO BIOLOGICAMENTE ATIVO, E COMPOSIçãO DE LIPOSSOMOS A presente invenção fornece composições de lipossomos que contêm um composto biologicamente ativo e métodos de produção destas. Os métodos da invenção oferecem capacidade de produzir composições de lipossomos contendo NSAIDs e outros compostos biologicamente ativos, e capacidade de atingir eficiências de encapsulação muito altas em lipossomos uniformes e estáveis. Composições de lipossomos contendo agentes antivirais e agentes antifúngicos são também fornecidas. As composições de lipossomo da invenção são úteis para o tratamento de uma variedade de condições, incluindo, por exemplo, dor e inflamação, infeccções bacterianas e infecçlões virais.
BRPI0312152-6A 2002-06-21 2003-06-19 método de produção de lipossomos contendo um composto biologicamente ativo, e composição de lipossomos BR0312152A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39050802P 2002-06-21 2002-06-21
US10/366,584 US20030235610A1 (en) 2002-06-21 2003-02-12 Liposomes containing biologically active compounds
PCT/US2003/019719 WO2004000226A2 (en) 2002-06-21 2003-06-19 Liposomes containing biologically active compounds

Publications (1)

Publication Number Publication Date
BR0312152A true BR0312152A (pt) 2007-05-29

Family

ID=29739576

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312152-6A BR0312152A (pt) 2002-06-21 2003-06-19 método de produção de lipossomos contendo um composto biologicamente ativo, e composição de lipossomos

Country Status (9)

Country Link
US (1) US20030235610A1 (pt)
EP (1) EP1515698A4 (pt)
JP (1) JP2005536481A (pt)
CN (1) CN1674870A (pt)
AU (1) AU2003243733A1 (pt)
BR (1) BR0312152A (pt)
CA (1) CA2489806A1 (pt)
MX (1) MXPA04012917A (pt)
WO (1) WO2004000226A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201204410A (en) * 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
HUE026644T2 (en) * 2004-05-28 2016-07-28 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
US20060165641A1 (en) * 2005-01-18 2006-07-27 Kumar Pillai Cosmetic compositions containing combinations of hydroxamate derivatives and antioxidants in a liposomal delivery system
US8258181B2 (en) * 2005-03-23 2012-09-04 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
EP1888033B1 (en) * 2005-06-09 2014-02-19 Meda AB Method and composition for treating inflammatory disorders
US20090291132A1 (en) * 2008-01-04 2009-11-26 Brian Charles Keller Enhanced delivery of antifungal agents
US20090176795A1 (en) * 2008-01-04 2009-07-09 Brian Charles Keller Enhanced delivery of antifungal agents
WO2010041255A2 (en) 2008-10-07 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomal systems comprising sphingomyelin
MX2011006562A (es) * 2008-12-17 2011-09-27 Oncothyreon Inc Metodo para elaborar liposomas pequeños.
PL214538B1 (pl) * 2009-05-28 2013-08-30 P P F Hasco Lek Spolka Akcyjna Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen
BR112012028787A2 (pt) * 2010-05-10 2017-03-14 J Miller Joseph lipossomos terapêuticos e métodos para produzir e usar os mesmos
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
JP6194248B2 (ja) * 2010-10-28 2017-09-06 パシラ ファーマシューティカルズ インコーポレーテッド 非ステロイド性抗炎症薬の徐放性処方物
JP2014518841A (ja) 2011-02-24 2014-08-07 オンコシレオン インク． アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン
TR201103183A1 (tr) * 2011-04-01 2012-10-22 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Ketoprofen ve metilsülfonilmetanın topikal farmasötik bileşimleri.
KR101305721B1 (ko) * 2011-12-27 2013-09-06 가톨릭대학교 산학협력단 신생 혈관 생성 및 신생 림프관 생성 억제를 위한 설린닥의 신규한 제형 및 이를 포함하는 안질환의 치료용 조성물
JP2015512371A (ja) * 2012-03-23 2015-04-27 ザ・ユニバーシティ・オブ・クイーンズランド 免疫調節性作用物質およびその使用
JP6471407B2 (ja) * 2013-12-25 2019-02-20 サンスター株式会社 口腔又は咽喉用組成物
JP6486601B2 (ja) * 2014-03-28 2019-03-20 サンスター株式会社 オーラルケア組成物
US20170049701A1 (en) * 2015-08-05 2017-02-23 Steven M. Kushner Clustoidal multilamellar soy lecithin phospholipid structures for transdermal, transmucosal, or oral delivery, improved intestinal absorption, and improved bioavailability of nutrients
EP3397241A1 (en) * 2015-12-30 2018-11-07 Asafov, Alexander Vilenovich Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses
KR101732844B1 (ko) * 2016-02-04 2017-05-08 강원대학교산학협력단 국소 피부 전달용 항염증 지질 나노 전달체를 포함하는 피부염 치료 또는 예방용 조성물
CN109983013A (zh) 2016-11-18 2019-07-05 帕西拉制药有限公司 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
CN113712990A (zh) * 2021-08-04 2021-11-30 北京斯利安健康科技有限公司 一种组合物及其制备方法与应用
WO2024077071A2 (en) * 2022-10-05 2024-04-11 The Johns Hopkins University Nanoparticles for delivery of immunoregulatory materials to t cells

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888176A (en) * 1984-05-21 1989-12-19 Massachusetts Institute Of Technology Controlled drug delivery high molecular weight polyanhydrides
GB8319766D0 (en) * 1983-07-22 1983-08-24 Graham N B Controlled release device
US4891225A (en) * 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
EP0177223B1 (en) * 1984-09-24 1990-02-28 Michael Mezei Pharmaceutical multi-phase composition
US4839276A (en) * 1984-12-05 1989-06-13 Technicon Instruments Corporation Interference - resistant liposome specific binding assay
IN166447B (pt) * 1985-11-27 1990-05-12 Ethicon Inc
US4839175A (en) * 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
US4877619A (en) * 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
US5525348A (en) * 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
PH31064A (en) * 1990-09-07 1998-02-05 Nycomed As Of Nycoveten Polymers containing diester units.
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
GB9111611D0 (en) * 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
WO1993015718A1 (en) * 1992-02-12 1993-08-19 Janssen Farmaceutici S.P.A. Liposomal piroxicam formulations
GB9204918D0 (en) * 1992-03-06 1992-04-22 Nycomed As Chemical compounds
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5562652A (en) * 1994-10-07 1996-10-08 Davis; William M. Antiseptic medical apparatus
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US5912225A (en) * 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
US5854382A (en) * 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
US6033708A (en) * 1997-09-30 2000-03-07 The United States Of America As Represented By The Secretary Of The Navy Method for producing sterile filterable liposome dispersion

Also Published As

Publication number Publication date
WO2004000226A3 (en) 2004-08-05
EP1515698A4 (en) 2005-09-14
JP2005536481A (ja) 2005-12-02
AU2003243733A1 (en) 2004-01-06
CN1674870A (zh) 2005-09-28
EP1515698A2 (en) 2005-03-23
US20030235610A1 (en) 2003-12-25
CA2489806A1 (en) 2003-12-31
MXPA04012917A (es) 2005-10-18
WO2004000226A2 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
WO2004000226A3 (en) Liposomes containing biologically active compounds
BR0110492A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto
BRPI0511132A (pt) derivados de pirimidina e composição farmacêutica compreendendo os mesmos
BR0110573A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0007781A (pt) Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf
DE60230327D1 (de) Polymorphe von clopidogrel-hydrogensulfat
BR0200782A (pt) Compostos para o tratamento da isquemia
MXPA05013752A (es) Procedimiento e intermediarios para la preparacion de (1r,2s,5s)-6,6-dimetil-3-azabiciclo[3,1,0]exan-2-carboxilatos o sales de los mismos.
PE20061107A1 (es) Composiciones de tigeciclina y metodos para su preparacion
MY142109A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
BRPI0412321A (pt) limpeza de membranas de filtração com peróxidos
UY27368A1 (es) Nuevos compuestos
PT1047397E (pt) Composicoes topicas para aumento da producao de glutationa
MEP10408A (en) Platinum derivative pharmaceutical formulations
PT1530465E (pt) Processo para produção de uma preparação lipossomal catiónica que compreende um composto lipofílico
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
PA8576201A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
DE602004024213D1 (en) Aminopropanolderivate
AR018357A1 (es) Acido petroselinico en una composicion y en un metodo para reducir o eliminar la irritacion o la picazon de la piel inducida por los alfa-hidroxiacidos
DE502006005523D1 (de) Pentafluorsulfanyl-substituierte verbindung und deren verwendung zur herstellung von arzneimitteln
EP4582410A4 (en) CATIONIC LIPID COMPOUND EXHIBITING HIGH EFFICACY, LOW TOXICITY AND STABLE EXPRESSION, AND COMPOSITION COMPRISING IT
WO2004078105A3 (fr) Composition de fondaparinux sodique de haute purete

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.